Amneal Pharm. LLC v. Food & Drug Admin. (2018)

green · 10 citation events across 2 courts. Showing the 4 strongest citers on record (one row per citing case, strongest signal kept).

All Green 4

Sort: By significance · Most recent

green Teva Pharm. United States, Inc. v. Azar (2019)

Rule Authority · D.C. Cir.

LLC , 285 F.Supp.3d at 333 (describing process); Dkt. 26 at 19, and approval is by no means a forgone conclusion.

describing process

green Norwich Pharmaceuticals, Inc. v. Becerra (2023)

Rule Authority · D.D.C. · 2 citations in this opinion

LLC v. Food & Drug Admin. , 285 F. Supp. 3d 328, 334 (D.D.C. 2018) (“To ‘compensate [generic] manufacturers for research and development costs as well as the risk of litigation from patent holders,’ Congress enacted an incentive for generic drug manufacturers to submit ANDAs and, if necessary, to engage in patent litigation.” (quoting Teva Pharm., USA, Inc. v. Leavitt, 548 F.3d 103, 104 (D.C.

green Teva Pharmaceuticals USA, Inc. v. Azar, II (2019)

Rule Authority · D.D.C. · 2 citations in this opinion

LLC v. FDA, 285 F. Supp. 3d 328, 332 (D.D.C. 2018).

green Sti Pharma, LLC v. Azar (2020)

Rule Authority · D.D.C.

LLC v. FDA, 285 F. Supp. 3d 328, 333 (D.D.C. 2018).